Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137)

Carcinoma of the Head and Neck Clinical Trial

— MASTERKEY232  

Official title:

A Phase 1b/3 Multicenter, Randomized, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab for the Treatment of Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02626000
• Other study ID #: 20130232
• Secondary ID: 20130232 / KEYNO
• Status: Completed
• Phase: Phase 1
• Start date: April 6, 2016
• Est. completion date: August 28, 2020

Study information

• Verified date: August 2021
• Source: Amgen
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study was to evaluate the safety, as assessed by incidence of dose limiting toxicity (DLT), of talimogene laherparepvec in combination with pembrolizumab in adults with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).

Description:

This is a phase 1b/3, multicenter, clinical trial conducted in 2 parts (phase 1b and phase 3). In phase 1b talimogene laherparepvec is to be administered in combination with pembrolizumab to adults with recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN). Dose limiting toxicity (DLT) is to be evaluated based on the first 18 DLT-evaluable participants. An expansion cohort of up to an additional 22 treated patients could be enrolled to further evaluate the safety and to estimate the efficacy of the combination of talimogene laherparepvec with pembrolizumab and to support a decision to initiate the phase 3 part of the study. The phase 3 part of the study was designed as a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, as assessed by overall survival, of treatment with talimogene laherparepvec with pembrolizumab versus placebo with pembrolizumab in adults with recurrent or metastatic SCCHN, however, a decision was made not to proceed to the phase 3 part of the study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. completion date: August 28, 2020
• Est. primary completion date: November 2, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria

• Male or female age = 18 years at the time of informed consent

• Histologically confirmed diagnosis of metastatic or recurrent SCCHN of the oral cavity, oropharynx, hypopharynx, or larynx. Disease must be unsuitable for curative surgical resection and must not be amenable to curative radiotherapy.

• Disease must have progressed after treatment with a platinum-containing regimen and should be defined as one of the following:

i. disease progression or recurrence between 3 to 6 months of prior curatively intended multimodal therapy (which includes platinum therapy) for locoregionally advanced SCCHN.

ii. disease progression or recurrence after prior platinum therapy in the recurrent or metastatic setting Note: This criterion is only applicable for subjects who have not had treatment in the recurrent/metastatic setting

• Subject must be candidate for intralesional therapy administration defined as one or more of the following:

i. at least 1 injectable cutaneous, subcutaneous, or nodal SCCHN tumor = 10 mm in longest diameter ii. multiple injectable cutaneous, subcutaneous, or nodal SCCHN tumors that in aggregate have a longest diameter of = 10 mm Note: Mucosal surfaces of tumor lesions and visceral metastases should not be injected.

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

• Adequate organ function determined within 14 days prior to enrollment

• Female subject of childbearing potential must have a negative pregnancy test within 72 hours prior to enrollment.

• Other Inclusion Criteria May Apply

Exclusion Criteria

• Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.

• Primary nasopharyngeal carcinoma.

• Subject at risk of airway compromise in the event of postinjection tumor swelling/inflammation based on investigator judgment.

• Phase 3: Previous treatment with 3 or more systemic regimens given for recurrent and/or metastatic disease

• History of other malignancy within the past 3 years

• History of interstitial lung disease (ILD).

• Prior therapy with talimogene laherparepvec, pembrolizumab, other anti-PD-1, any other antibody or drug specifically targeting T-cell co-stimulation or immune check point pathway.

• History or evidence of active autoimmune disease that has required systemic treatment in the past 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs).

• Evidence of clinically significant immunosuppression

• Active herpetic skin lesions or prior complications of herpetic infection (eg, herpetic keratitis or encephalitis).

• Requires intermittent or chronic treatment with an antiherpetic drug (eg, acyclovir), other than intermittent topical use.

• Prior chemotherapy, radiotherapy, biological cancer therapy, targeted therapy, or major surgery within 28 days prior to enrollment or has not recovered to Common Terminology Criteria for Adverse Events (CTCAE) grade 1 or better from adverse event due to cancer therapy administered more than 28 days prior to enrollment.

• Expected to require other cancer therapy while on study with the exception of local palliative radiation treatment to the site of bone and other metastasis.

• Known human immunodeficiency virus (HIV) disease.

• Has acute or chronic active hepatitis B virus or hepatitis C virus infection or received treatment with nucleotide analogs such as those used in the treatment of hepatitis B virus (eg, lamivudine, adefovir, tenofovir, telbivudine, entecavir), ribavirin, or interferon alpha within 12 weeks of initiation of study treatment.

• Received live vaccine within 28 days prior to enrollment.

• Subject is pregnant or breast-feeding, or expecting to conceive or father children within the duration of the trial

• Female subject of childbearing potential or male subject of reproductive potential who is unwilling to use acceptable method(s) of effective contraception during study treatment and through 3 months after the last dose of talimogene laherparepvec/placebo or 4 months after the last dose of pembrolizumab, whichever is later.

• Sexually active subjects or their partners unwilling to use male or female latex condom to avoid potential viral transmission during sexual contact while on treatment and within 30 days after treatment with talimogene laherparepvec/placebo.

• Subject who is unwilling to minimize exposure with his/her blood or other body fluids to individuals who are at higher risks for herpes simplex virus type 1 (HSV-1)-induced complications (eg, immunosuppressed individuals, HIV-positive individuals, pregnant women, or children under the age of 1 year) during talimogene laherparepvec treatment and through 30 days after the last dose of talimogene laherparepvec

• Has history of (non-infectious) pneumonitis that required steriods or current pneumonitis

• Subjects with tumor that directly contacts or encases a major blood vessel AND there is ulceration and/or fungation onto the skin surface

• History of re-irradiation to a field which includes the carotid arteries

• Other Exclusion Criteria May Apply

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma of the Head and Neck
• Carcinoma, Squamous Cell
• Squamous Cell Carcinoma of Head and Neck

Intervention

Drug:
• Talimogene Laherparepvec
The initial dose of talimogene laherparepvec is up to 8.0 mL of 106 PFU/mL. Subsequent doses of talimogene laherparepvec are up to 8.0 mL of 108 PFU/mL.

Biological:
• Pembrolizumab
Administered as a 30-minute intravenous infusion at a dose of 200 mg Q3W

Locations

Country	Name	City	State
Australia	Research Site	Geelong	Victoria
Australia	Research Site	Melbourne	Victoria
Austria	Research Site	Salzburg
Belgium	Research Site	Bruxelles
Belgium	Research Site	Wilrijk
Canada	Research Site	Toronto	Ontario
France	Research Site	Bordeaux
France	Research Site	Pierre-Benite
France	Research Site	Toulouse cedex 9
Greece	Research Site	Athens
Greece	Research Site	Ioannina
Italy	Research Site	Milano
Spain	Research Site	L'Hospitalet de Llobregat	Cataluña
Spain	Research Site	Madrid
Spain	Research Site	Madrid
Spain	Research Site	Sevilla	Andalucía
Switzerland	Research Site	Bellinzona
Switzerland	Research Site	Geneva 14
Switzerland	Research Site	Zurich
United Kingdom	Research Site	Birmingham
United Kingdom	Research Site	London
United Kingdom	Research Site	London
United Kingdom	Research Site	Oxford
United Kingdom	Research Site	Sutton
United Kingdom	Research Site	Wirral
United States	Research Site	Billings	Montana
United States	Research Site	Canton	Ohio
United States	Research Site	Chicago	Illinois
United States	Research Site	Chicago	Illinois
United States	Research Site	Louisville	Kentucky
United States	Research Site	New York	New York
United States	Research Site	New York	New York
United States	Research Site	Newark	Delaware

Sponsors (2)

Lead Sponsor	Collaborator
Amgen	Merck Sharp & Dohme Corp.

Countries where clinical trial is conducted

United States,  Australia,  Austria,  Belgium,  Canada,  France,  Greece,  Italy,  Spain,  Switzerland,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With a Dose Limiting Toxicity (DLT)	The following toxicities (graded per the Common Terminology Criteria for Adverse Events v 4.0) were considered DLTs if judged by the investigator to be related to either study drug: grade 4 non-hematologic (non-laboratory) toxicity; = grade 3 pneumonitis; grade 3 non-hematologic toxicity for > 3 days with optimal supportive care; grade 3 fatigue was not classified as DLT, regardless of duration; any = grade 3 non-hematologic laboratory value if: medical intervention was required,; the abnormality led to hospitalization, or; the abnormality persisted at = grade 3 for > 1 week unless deemed not clinically important by investigator and sponsor; grade 3 or 4 febrile neutropenia; thrombocytopenia < 25 x 10?/L associated with bleeding event requiring intervention; serious herpetic event: herpetic encephalitis, encephalomyelitis, or disseminated herpetic infection; grade 5 toxicity; other intolerable toxicity leading to permanent discontinuation of either study drug.	First 6 weeks after the initial administration of talimogene laherparepvec and pembrolizumab in combination
Secondary	Objective Response Rate	Objective response rate was defined as the percentage of participants with a best overall response of complete response or partial response assessed by the investigator using immune-related Response Evaluation Criteria in Solid Tumors (irRECIST). Response was based on the size of tumors assessed by computed tomography (CT) or magnetic resonance imaging (MRI).; Complete response (iCR): Disappearance of all lesions (whether measurable or not and whether baseline or new) and confirmation by a repeat, consecutive assessment no less than 4 weeks from the date first documented was required. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm.; Partial response (iPR): Decrease in tumor burden = 30% relative to baseline. Confirmation by a consecutive assessment at least 4 weeks after first documentation required.; Analyses are presented below for both the unconfirmed and confirmed results.	Up to the primary analysis data cutoff date of 02 November 2017; median (minimum, maximum) time on follow-up was 14.36 (1.4, 67.0) weeks.
Secondary	Complete Response Rate	Complete response rate (iCRR) was defined as the percentage of participants with a best overall response of complete response assessed by the investigator using immune-related Response Evaluation Criteria in Solid Tumors (irRECIST). Response was based on the size of tumors assessed by computed tomography (CT) or magnetic resonance imaging (MRI).; Complete response (iCR): Disappearance of all lesions (whether measurable or not and whether baseline or new) and confirmation by a repeat, consecutive assessment no less than 4 weeks from the date first documented was required. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm.; Analyses are presented below for both the unconfirmed and confirmed results.	Up to the primary analysis data cutoff date of 02 November 2017; median (minimum, maximum) time on follow-up was 14.36 (1.4, 67.0) weeks.
Secondary	Best Overall Confirmed Response	Best overall visit response of iCR, iPR, stable disease (iSD), progressive disease (iPD) or unevaluable (iUE) based on investigator assessment using irRECIST.; iCR: Disappearance of all lesions (whether measurable or not and whether baseline or new). Any pathological lymph nodes (target or non-target) must have reduction in short axis to <10 mm.; iPR: Decrease in tumor size = 30% relative to baseline. iPD: Increase in tumor size = 20% and at least 5 mm absolute increase compared to nadir or qualitative worsening of non-target lesions or a new lesion.; iSD: Neither sufficient shrinkage to qualify for iCR or iPR nor sufficient increase to qualify for iPD.; iUE: Any baseline lesion which was not assessed or was unable to be evaluated leading to an inability to determine the status of that particular tumor.; Not Done: Radiographic imaging was not performed to evaluate the response. iCR, iPR, and iPD required confirmation by a consecutive assessment at least 4 weeks after first documentation.	Up to the primary analysis data cutoff date of 02 November 2017; median (minimum, maximum) time on follow-up was 14.36 (1.4, 67.0) weeks.
Secondary	Duration of Confirmed Response	Duration of response (iDOR) per irRECIST was defined as the time from the date of an initial response of iCR or iPR that was subsequently confirmed to the earlier of a participant overall response of iPD or death. Participants who did not end their response at the time of analysis were censored at their last evaluable tumor assessment.	Up to the primary analysis data cutoff date of 02 November 2017; median (minimum, maximum) time on follow-up was 14.36 (1.4, 67.0) weeks.
Secondary	Disease Control Rate	Disease control rate (iDCR) was defined as the percentage of participants with a best overall response of iCR or iPR or iSD assessed by the investigator using irRECIST.; Complete response (iCR): Disappearance of all lesions (whether measurable or not and whether baseline or new) and confirmation by a repeat, consecutive assessment no less than 4 weeks from the date first documented was required. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm.; Partial response (iPR): Decrease in tumor burden = 30% relative to baseline. Confirmation by a consecutive assessment at least 4 weeks after first documentation required.; Stable disease (iSD): Neither sufficient shrinkage to qualify for iCR or iPR nor sufficient increase to qualify for iPD.; Analyses are presented below for both the unconfirmed and confirmed results.	Up to the primary analysis data cutoff date of 02 November 2017; median (minimum, maximum) time on follow-up was 14.36 (1.4, 67.0) weeks.
Secondary	Progression Free Survival	Progression-free survival (iPFS) per irRECIST was defined as the interval from first dose to the earlier of a participant overall response of iPD or death from any cause; otherwise, iPFS was censored at the last evaluable tumor assessment. The initial date of an iPD that was consecutively confirmed was used.	Up to the primary analysis data cutoff date of 02 November 2017; median (minimum, maximum) time on follow-up was 14.36 (1.4, 67.0) weeks.
Secondary	Overall Survival	Overall survival (OS) was defined as the interval from first dose to the event of death from any cause; otherwise, OS was censored at the date the participant was last known to be alive.	Up to the primary analysis data cutoff date of 02 November 2017; median (minimum, maximum) time on follow-up was 14.36 (1.4, 67.0) weeks.
Secondary	Number of Participants With Adverse Events	The severity of adverse events was assessed by the investigator according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, and based on the following scale: Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life-threatening, Grade 5 = death.; A serious adverse event is an AE that met at least 1 of the following serious criteria: fatal; life threatening; required in-patient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; congenital anomaly/birth defect; other medically important serious event.	From first dose of study drug to 30 days after last dose; the median (range) duration of treatment was 5.6 (0.1 to 75.3) weeks for talimogene laherparepvec and 6.1 (0.1, 105.3) weeks for pembrolizumab.

External Links

•   AmgenTrials clinical trials website